Trump faces stock manipulation charges after 90-day tariff pause
Listen to article
US President Donald Trump's unexpected move to pause tariffs on most trading partners sent global markets surging on Wednesday, but also drew swift criticism from political opponents, including Senator Elizabeth Warren, who has accused the administration of market manipulation.
The announcement, made less than 24 hours after Trump imposed steep new duties, was widely seen as a dramatic reversal — one that briefly cooled trade tensions and lifted investor sentiment. Global indices closed sharply higher, and the US dollar gained ground as traders recalibrated their outlook.
Despite the immediate market euphoria, the policy shift has triggered a wave of scrutiny. Senator Warren has called for a formal investigation, alleging that the White House may be using tariff policy to create artificial market volatility that benefits wealthy donors and insiders.
'This smells like corruption,' Warren posted on X. 'Trump's tariff flip-flopping may have allowed insiders to cash in, while working Americans and small businesses are left paying the price.'
The Massachusetts senator further argued that Trump's erratic tariff actions — including raising levies on Chinese imports to 125% while pausing them for others — have contributed to rising economic uncertainty and damaged investor confidence.
Market analysts are divided on the long-term impact. Some see the tariff suspension as a welcome de-escalation in global trade tensions. Others warn that the unpredictability of U.S. trade policy under Trump continues to pose serious risks.
'This on-again, off-again approach to tariffs undermines stability,' said Sarah Lin, a trade policy analyst at the Global Markets Institute. 'It creates a climate where policy becomes impossible to predict — and markets hate unpredictability.'
The White House has not commented on the allegations, but the President previously defended his tariff strategy as a necessary tool to protect U.S. industries and to pressure trading partners, particularly China.
While some tariffs remain paused for 90 days, those aimed at China are set to stay in place — keeping trade tensions with Beijing high. In the meantime, markets continue to watch closely, navigating a policy landscape that shifts by the day.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
39 minutes ago
- Business Recorder
AstraZeneca signs AI research deal with China's CSPC for chronic diseases
AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which would help the Anglo-Swedish drugmaker develop therapies for chronic conditions, it said on Friday. The deal marks the latest effort by AstraZeneca to revive its business in China, its second-biggest market, where it has faced several challenges including the arrest of its China president last year and potential fines related to imports. Under Friday's agreement, the two companies will collaborate to discover and develop pre-clinical candidates, including a small molecule oral therapy for immunological diseases, with CSPC conducting AI-driven research in Shijiazhuang City. 'This strategic research collaboration underscores our commitment to innovation to tackle chronic diseases which impact over two billion people globally,' AstraZeneca executive Sharon Barr said in a statement. Friday's agreement follows AstraZeneca's announcement in March that it will invest $2.5 billion in a R&D hub in Beijing, and it also marks further investment in AI following collaborations with Immunai, and Tempus AI. AstraZeneca will pay CSPC an upfront fee of $110 million. The Hong Kong-listed firm is also eligible to receive up to $1.62 billion for reaching development milestones and $3.6 billion linked to sales-related milestones, the groups said in separate statements. They signed a licensing deal last October in which AstraZeneca agreed to pay up to $1.92 billion to CSPC to develop a candidate which would boost its cardiovascular pipeline. AstraZeneca and CSPC both have wide-ranging pipeline portfolios, including cancer treatments and those targeting cardiovascular diseases. However, about 80% of CSPC's total revenue comes from its finished drug segment, according Morningstar analysts. The Chinese group said last month it was in negotiations with third parties on new licensing and collaboration. Friday's agreement also gives AstraZeneca the rights to exercise options for exclusive licenses for candidates identified as part of the collaboration.
Business Recorder
an hour ago
- Business Recorder
India, China agree to expedite resumption of direct flights as ties improve
India and China have agreed to expedite the resumption of direct air services and step up communication, the two countries' foreign ministries said on Friday, as Beijing and New Delhi continue to mend bilateral ties. The ministries' statements came after a meeting on Thursday of Indian Foreign Secretary Vikram Misri and Chinese Vice Foreign Minister Sun Weidong, who is visiting India. The two countries reached an agreement in October regarding patrolling along their Himalayan border, thawing a standoff that began in 2020 and had strained bilateral ties, impacting areas from trade to technology to air travel. China expresses concern, offers help to resolve Pakistan, India conflict Sun said in the meeting that the two sides should properly handle disputes and differences, and jointly play a constructive role in maintaining international and regional peace and stability, according to the Chinese ministry's statement. The two sides agreed to continue to stabilise and rebuild ties, the Indian ministry's statement said. In January, the neighbours agreed to work on resolving trade and economic differences, a move expected to boost their aviation sectors.
Business Recorder
an hour ago
- Business Recorder
Copper, other metals drop as investors shed risk after Israel strikes Iran
LONDON: Prices of copper and other industrial metals fell on Friday, weighed down by a stronger dollar as investors sold risky assets after Israel attacked Iran. Benchmark three-month copper on the London Metal Exchange shed 1.3% to $9,575 a metric ton by 1010 GMT, the weakest since June 3. The dollar index climbed and world stock markets tumbled after Israel launched a large-scale military strike on Iran. A firmer dollar makes commodities priced in the U.S. currency more expensive for buyers using other currencies. 'The market is de-risking on copper and aluminium,' said Alastair Munro, senior base metals strategist at broker Marex. 'The key now will be whether the risk managers in the USA start to knock on the money managers' door saying you've got to reduce risk ahead of the weekend.' U.S. Comex copper futures dropped 1.9% to $4.74 a lb, bringing the premium of Comex over LME copper to $879 a ton. London copper rises; volatility fears linger Munro said much of the selling was by Commodity Trade Advisor (CTA) investment funds, which are largely driven by computer programs, while Chinese participants emerged at the lows to do some buying. In China, the most-traded aluminium contract on the Shanghai Futures Exchange (SHFE) gained for the third straight day, up 0.4% at 20,425 yuan per metric ton, outperforming other SHFE metals. 'Aluminium, compared with the other metals, has been performing rather strongly recently as demand from the domestic market has been robust, while SHFE stocks have been declining,' a Hangzhou-based analyst from a futures company said. Aluminium stocks in SHFE warehouses fell to 110,001 tons in the week ended June 13, the lowest since February 2024, having tumbled by 54% since late March. Among other metals, LME aluminium gave up 1.2% to $2,487.50 a ton, zinc fell 1.7% to $2,598.50, lead dipped 0.3% to $1,991.50, nickel slipped 0.2% to $15,165 and tin was down 0.1% to $32,600.
